Sun Pharma completes acquisition of Antibe Therapeutics Inc.
Sun Pharmaceutical Industries announced today that it has completed the 100% acquisition of Antibe Therapeutics Inc., a Canadian company, through its subsidiary, TARO Pharmaceuticals Inc. The acquisition, initially announced on January 16, 2025, was finalized on March 18, 2025. The total consideration for the acquisition is CAD 4.5 million. This move is expected to strengthen Sun Pharma's portfolio and presence in the North American market. Sun Pharmaceutical Industries, listed on the National Stock Exchange of India (SUNPHARMA) and the BSE Limited (524715), is a global pharmaceutical company.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
News Alerts
Get instant email alerts when Sun Pharmaceutical Industries publishes news
Free account required • Unsubscribe anytime